TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

Kesimpta is such a drug, taken as an injection under the skin once a month. According to the MS Trust , it reduces the number of relapses by about two-thirds (70%). Safety, efficacy, and adherence ...

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

Ofatumumab (Kesimpta) is a human-made protein that attaches itself to certain B cells and weakens them so they can’t cause damage. Ofatumumab is FDA approved for: Clinically isolated syndrome ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...

The company’s revenue soared by 29%, reaching DKK 15,085 million, primarily due to increased royalties from products like DARZALEX and Kesimpta. Notable strategic advancements include the European ...